Literature DB >> 24875352

Sources of European drug consumption data at a country level.

Pili Ferrer1, Elena Ballarín, Mònica Sabaté, Joan-Ramon Laporte, Marieke Schoonen, Marietta Rottenkolber, Joan Fortuny, Joerg Hasford, Iain Tatt, Luisa Ibáñez.   

Abstract

OBJECTIVES: This study aimed at outlining the characteristics of nationwide administrative databases monitoring drug consumption in Europe.
METHODS: Internet and bibliographic databases (April 2010) were searched and experts in drug utilization (DU) research interviewed to find nationwide administrative medicines consumption databases in Europe, with data for the out- and inpatient healthcare sector. A questionnaire was developed to gather additional information. We collected data providers, websites, accessibility, data sources, healthcare settings, population coverage, medicines-related data, patient and prescriber data, periods covered, and linkage to other databases.
RESULTS: Thirty-one administrative nationwide medicine consumption databases in 25 countries were identified. Questionnaires were responded for 20 databases. Eleven provided wholesalers' sales data, 11 on reimbursed, 5 on prescribed, and 4 on dispensing medicines. Fifteen databases provided inpatient drug consumption data, mainly wholesalers' sales.
CONCLUSIONS: Nationwide administrative databases are of value to all stakeholders involved in the conduct and interpretation of post-marketing safety studies, and in the conduct of DU research. The endorsement of the anatomical therapeutic chemical/defined daily dose methodology by these databases contributes to data harmonization. However, there is still a lack of information on inpatient medicines consumption at a patient-level.

Entities:  

Mesh:

Year:  2014        PMID: 24875352     DOI: 10.1007/s00038-014-0564-8

Source DB:  PubMed          Journal:  Int J Public Health        ISSN: 1661-8556            Impact factor:   3.380


  29 in total

1.  Development of a prescribing indicator for objective quantification of antibiotic usage in secondary care.

Authors:  Chris Curtis; John Marriott; Chris Langley
Journal:  J Antimicrob Chemother       Date:  2004-07-21       Impact factor: 5.790

2.  Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications.

Authors:  Brian Godman; William Shrank; Morten Andersen; Christian Berg; Iain Bishop; Thomas Burkhardt; Kristina Garuoliene; Harald Herholz; Roberta Joppi; Marija Kalaba; Ott Laius; Diane McGinn; Vita Samaluk; Catherine Sermet; Ulrich Schwabe; Inês Teixeira; Lesley Tilson; F Cankat Tulunay; Vera Vlahović-Palčevski; Kamila Wendykowska; Björn Wettermark; Corinne Zara; Lars L Gustafsson
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2010-12       Impact factor: 2.217

3.  An additional measure for quantifying antibiotic use in hospitals.

Authors:  P M G Filius; T B Y Liem; P D van der Linden; R Janknegt; S Natsch; A G Vulto; H A Verbrugh
Journal:  J Antimicrob Chemother       Date:  2005-04-06       Impact factor: 5.790

Review 4.  The Nordic countries as a cohort for pharmacoepidemiological research.

Authors:  Kari Furu; Björn Wettermark; Morten Andersen; Jaana E Martikainen; Anna Birna Almarsdottir; Henrik Toft Sørensen
Journal:  Basic Clin Pharmacol Toxicol       Date:  2009-12-04       Impact factor: 4.080

5.  Antiepileptic drug use in community-dwelling and institutionalized elderly: a nationwide study of over 1,300,000 older people.

Authors:  Kristina Johnell; Johan Fastbom
Journal:  Eur J Clin Pharmacol       Date:  2011-04-28       Impact factor: 2.953

Review 6.  A framework for evaluation of secondary data sources for epidemiological research.

Authors:  H T Sorensen; S Sabroe; J Olsen
Journal:  Int J Epidemiol       Date:  1996-04       Impact factor: 7.196

7.  Prescribing of antidiabetic therapies in Ireland: 10-year trends 2003-2012.

Authors:  N L Zaharan; D Williams; K Bennett
Journal:  Ir J Med Sci       Date:  2013-09-07       Impact factor: 1.568

Review 8.  Excess risk of hip fractures attributable to the use of antidepressants in five European countries and the USA.

Authors:  D Prieto-Alhambra; H Petri; J S B Goldenberg; T P Khong; O H Klungel; N J Robinson; F de Vries
Journal:  Osteoporos Int       Date:  2014-01-22       Impact factor: 4.507

9.  A population-based study of dosing and persistence with anti-dementia medications.

Authors:  Linda Brewer; Kathleen Bennett; Cora McGreevy; David Williams
Journal:  Eur J Clin Pharmacol       Date:  2013-02-27       Impact factor: 2.953

10.  Impact analysis of the discontinuation of reimbursement: the case of oral contraceptives.

Authors:  Pieter Stolk; Sebastian Schneeweiss; Hubert G M Leufkens; Eibert R Heerdink
Journal:  Contraception       Date:  2008-08-28       Impact factor: 3.375

View more
  4 in total

1.  Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries.

Authors:  Alice Pisana; Björn Wettermark; Amanj Kurdi; Biljana Tubic; Caridad Pontes; Corinne Zara; Eric Van Ganse; Guenka Petrova; Ileana Mardare; Jurij Fürst; Marta Roig-Izquierdo; Oyvind Melien; Patricia Vella Bonanno; Rita Banzi; Vanda Marković-Peković; Zornitsa Mitkova; Brian Godman
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

2.  Data Resource Profile: The Scottish National Prescribing Information System (PIS).

Authors:  Samantha Alvarez-Madrazo; Stuart McTaggart; Clifford Nangle; Elizabeth Nicholson; Marion Bennie
Journal:  Int J Epidemiol       Date:  2016-05-10       Impact factor: 7.196

3.  The first report of Japanese antimicrobial use measured by national database based on health insurance claims data (2011-2013): comparison with sales data, and trend analysis stratified by antimicrobial category and age group.

Authors:  Daisuke Yamasaki; Masaki Tanabe; Yuichi Muraki; Genta Kato; Norio Ohmagari; Tetsuya Yagi
Journal:  Infection       Date:  2017-12-22       Impact factor: 3.553

4.  A framework for monitoring of new drugs in Sweden.

Authors:  Thomas Cars; Lars Lindhagen; Johan Sundström
Journal:  Ups J Med Sci       Date:  2019-01-28       Impact factor: 2.384

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.